Haplo-cord HCT offered improved 2-year OS (72.7% vs 61.0%) and DFS (67.0% vs 49.6%) compared with haplo HCT alone.
It is able to continue as a going concern until Sep 30, 2026, but the future beyond that is not certain, says board Read more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback